This one has potential.
It's a re-opening stock, that's why the insiders are buying it.
------------------------------------
The unprecedented events of the COVID-19 pandemic, and its unpredictable duration, in the regions where we have customers, employees and distributors have had an adverse effect on our sales of ILUVIEN and thus on our net revenues and may in the future have an adverse effect on our liquidity and financial condition. These adverse effects of the pandemic on us have resulted from the following, among other factors:
•Limitations imposed by governments and private parties on in-person access to physicians adversely affect us in at least two ways. First, these limitations can affect patient access to treatment. Because ILUVIEN is administered only by an injection into the eye, telemedicine is not a viable substitute when administration of treatment is required. Second, limitations on in-person access to physicians, such as obtaining access to government-controlled facilities, also makes it difficult or impossible for our sales representatives (including those employed by our distributors) to meet with retina specialists and their staff to educate them about ILUVIEN. We currently or have recently faced these limitations in Veterans Administration hospitals, Kaiser Permanente hospitals, and certain hospitals in Germany and the other countries where we market ILUVIEN
•Patients’ concerns about their personal health during the COVID-19 pandemic have also negatively affected our business. Prior to the pandemic, most of our ILUVIEN sales were driven by the use of ILUVIEN to treat diabetic macular edema, or DME. Given that health authorities have cited diabetes as a factor that places a person at higher risk for severe illness from the COVID-19 pandemic, many DME patients have been hesitant or even unwilling to visit their physicians in person (even if otherwise permitted) for fear of contracting the COVID-19 coronavirus. In addition, the adverse effect of DME on a patient’s vision can progress slowly over time, and patients may defer seeking treatment until their loss of vision is significant, which we believe may negatively affect user demand for ILUVIEN.
•In addition to the effects of limitations on in-person access to physicians, limitations on travel earlier in 2021 within and between the countries in which we market and sell ILUVIEN, as well as various types of lockdown or restricted access orders, curtailed our in-person marketing activities, and those limitations could be imposed again in the future.
•The occurrence of COVID-19 pandemic “waves” in individual countries and the uneven level of vaccination across countries have created further difficulty in planning and forecasting business activity and resulted in a reduced ability to consistently and effectively market ILUVIEN in affected countries; and
31
Table of Contents
•As physicians gain increased access to patients, they may give a higher priority to patients with acute illnesses before treating patients with chronic illnesses such as DME, thereby reducing or delaying the number of ILUVIEN treatments that might otherwise have been performed.
These limitations and other effects of the COVID-19 pandemic have had an adverse impact on our revenues beginning late in the first quarter of 2020 and continuing through the date of this report. We expect these factors to continue to adversely impact our revenue and capital resources, and the extent and duration of that impact is uncertain at this time, particularly in light of the emergence of COVID-19 variants that increase the transmissibility of the coronavirus. (Please refer to “Special Note Regarding Forward-Looking Statements and Projections” above.)
In response to these developments, we have implemented measures to mitigate the impact of the pandemic on our financial position and operations. These measures include the following:
•We are continuing to monitor the effects of the SARS-CoV-2 variants and to manage our cost structure where possible to mitigate any anticipated loss of revenue in those markets that are affected.
•We are focusing our spending in certain countries where access is less restricted in order to serve our customers and patients through either direct or alternative forms of engagement.
Transactions with Ocumension Therapeutics
On April 14, 2021, we entered into a transaction with Ocumension Therapeutics, incorporated in the Cayman Islands with limited liability (Ocumension), or one of its affiliates. In the Ocumension transaction, we received a total of $20.0 million in cash under two agreements:
•a Share Purchase Agreement with Ocumension, pursuant to which we offered and sold to Ocumension 1,144,945 shares of our common stock at a purchase price of $8.734044 per share, or $10.0 million in total; and
•an Exclusive License Agreement (the Ocumension License Agreement) with a wholly owned subsidiary of Ocumension, pursuant to which we granted an exclusive license for the development and commercialization of our 190 microgram fluocinolone acetonide intravitreal implant in applicator under Ocumension’s own branded label in China, East Asia, and the Western Pacific, in exchange for a nonrefundable upfront payment of $10.0 million and aggregated potential sales milestone payments of up to $89.0 million upon achievement by the Ocumension subsidiary of specified amounts of net sales of the licensed product in in the future. We recognized $11.0 million in license revenue from the Ocumension transaction (including the value of a warrant subscription agreement, which we received as consideration, to purchase 1,000,000 shares of Ocumension Therapeutics during a period of four years), in accordance with ASC 606, Revenue from Contracts with Customers, with the remaining approximate $300,000 in consideration received classified as deferred revenue that will be recognized over the remaining term of the license agreement once Ocumension begins to sell products. Revenue from the Ocumension License Agreement is included within net revenue in the accompanying condensed consolidated statements of operations.
I've never found anything as easy as this shorting.
